|Bid||140.00 x 800|
|Ask||164.98 x 800|
|Day's Range||162.91 - 166.65|
|52 Week Range||119.38 - 190.36|
|Beta (3Y Monthly)||1.23|
|PE Ratio (TTM)||18.65|
|Earnings Date||Jul 23, 2019 - Jul 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||174.33|
Raymond James analyst John Ransom this week named two potential targets for Walgreens Boots Alliance (Nasdaq: WBA) – LabCorp and drug wholesaler AmerisourceBergen (NYSE: ABC).
LabCorp® (LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced the availability of a newly-approved companion diagnostic by the U.S. Food and Drug Administration (FDA), the therascreen® FGFR mutation assay by RGQ RT-PCR, which is now available for ordering from LabCorp and its Integrated Oncology specialty laboratory.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Today we'll look at Laboratory Corporation of America Holdings (NYSE:LH) and reflect on its potential a...
Laboratory Corporation of America Holdings NYSE:LHView full report here! Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for LH with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting LH. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $1.82 billion over the last one-month into ETFs that hold LH are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. LH credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
LabCorp® (LH) today announced that its Annual Meeting of Shareholders will be webcast live beginning May 9, 2019, at 9:00 a.m. Eastern Daylight Time via the Company website at www.LabCorp.com. LabCorp (LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster, and uses technology to improve the delivery of care.
Despite increasing acquisitions and favorable mix, the disposition of certain businesses and the implementation of PAMA are adversely affecting LabCorp's (LH) growth.
On a per-share basis, the Burlington, North Carolina-based company said it had profit of $1.86. Earnings, adjusted for one-time gains and costs, were $2.62 per share. The results beat Wall Street expectations. ...
BURLINGTON, N.C.-- -- Q1 revenue of $2.79 billion, down 2% from $2.85 billion last year Q1 diluted EPS of $1.86, up 11% from $1.67 last year; Q1 adjusted EPS of $2.62, down 6% from $2.78 last year 2019 adjusted EPS guidance increased to $11.05 to $11.45, from $11.00 to $11.40 2019 free cash flow guidance of $950 million to $1.05 billion, unchanged from prior guidance LabCorp® today announced results ...
Within Covance Drug Development, LabCorp (LH) is expected to drive profitable growth through expanded solutions and enhanced operational capabilities.
LabCorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OmniSeq®, a CAP-accredited, molecular diagnostics spin-out of Roswell Park Comprehensive Cancer Center, and LabCorp® (LH), a leading global life sciences company, announced today an extension of their exclusive distribution agreement as well as an additional investment by LabCorp. The distribution agreement and LabCorp’s initial investment in OmniSeq’s Series B financing round were first announced in August 2017. The distribution agreement originally provided LabCorp with exclusive distribution rights for the OmniSeq Comprehensive and Immune Report Card clinical assays.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Envigo Laboratories Inc. New York, April 22, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Envigo Laboratories Inc. ("Envigo") and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Moody's Investors Service ("Moody's") placed the ratings of Envigo Laboratories Inc. under review for upgrade. Ratings under review for upgrade include the Caa2 Corporate Family Rating, Caa2-PD Probability of Default Rating, the B3 senior secured first lien credit facilities and Caa3 senior secured second lien credit facilities. The announced sale of Envigo's nonclinical contract research services business to LabCorp and the concurrent acquisition of LabCorp's US research models and services business is credit positive given the improvement in liquidity due to net proceeds to be received of $485 million.
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Laboratory Corporation of America Holdings and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
Strong analytical instruments business, product portfolio expansion and prudent growth strategy are likely to support Thermo Fisher (TMO) in Q1. However, forex might act as a dampener.
Higher Invisalign case volume, solid show by Clear Aligner segment and anticipated sturdy growth at Scanner and Service business are likely to support Align Technology (ALGN) in Q1. However, operating expenses are likely to act as dampeners.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. To keep the lesson grounded in practicality, we'l...
BURLINGTON, N.C. & EAST MILLSTONE, N.J.-- -- LabCorp will purchase Envigo’s nonclinical contract research services business, expanding the global reach and capabilities of Covance’s nonclinical drug development business Envigo’s research models and services business will purchase Covance’s research products business located in the United States, combining two complementary businesses into a new comprehensive ...
Kerrii B. Anderson, former CEO and President of Wendy's International, Inc., and Jeff M. Fettig, former Chairman and CEO of Whirlpool Corporation, join the Board CLEVELAND , April 17, 2019 /PRNewswire/ ...
Rite Aid's board clears the way for a 1-for-20 reverse stock split later this month. Booking Holdings, LabCorp, and Citi have gone on to move higher after going this route.